EDETEK Announces New Insights on Conducting End-to-End Clinical Trial Solutions

Presentation will Feature the Fully Integrated Aspects of EDETEK's Services Within the CONFORM™ Platform, Ensuring Flawlessly Orchestrated Biometric Data Management

EDETEK Inc., a leading global provider of specialized software and services for the biopharma, devices, and diagnostics industries, announced today that it will present at the 2024 DPHARM (Disruptive Innovations to Modernize Clinical Research – #DPharm2024) conference. This session, entitled, “Transforming Clinical Trials: From Reactive to Predictive,” takes place during the DPHARM Innovative Collaborations Track C, on Tuesday, September 17, 2024, at 4:10pm EDT.

“We are leading the trend from a reactive to a predictive approach in clinical trials with a unified, end-to-end platform that connects all stakeholders and automates key processes,” said Munther Baara, VP, Product Strategy & Innovation, EDETEK, Inc. “Collecting data in real-time is critical to creating a frictionless and seamless experience for clinical trial participants. At the event, I will share how our solution automatically applies complex algorithms to data in near real-time, enabling sites to make timely decisions while patients are at their study visits. This ensures that decisions about staying on the investigational product or switching to rescue treatment can be made immediately, alleviating the burden on sick patients and their caregivers who would otherwise need to return for results the next day.”

Most organizations offer a range of biometric services but often focus only on specific areas or lack seamless integration. At EDETEK our CONFORM™ platform delivers solutions that utilize AI resulting in a powerful end-to-end platform for complex trials of today and digital trials of the future.

“By integrating systems and optimizing decision-making, this approach reduces the burden on sponsors, sites, and patients,” explains Mr. Baara. “Our cutting-edge innovations accelerate timelines, and enhance overall data quality, driving faster and more reliable clinical trial outcomes.”

The EDETEK CONFORM™ platform has emerged as a transformative business and technical solution for increasingly complex clinical trials. It creates an end-to-end digital interoperable ecosystem to rapidly orchestrate the movement, evaluation, and submission of clinical research data through a seamless, transparent experience for all stakeholders.

CONFORM provides sponsors the ability to transfer large volumes of data in near real-time and delivers expandable storage capacity, flexible workflows with transformations, mappings, validation, search, and flagging capabilities. CONFORM also ensures full data lineage and improved quality, due to proactive monitoring of data acquisitions and the ability for multiple stakeholders to quickly access and review data. It performs secure data exchange while maintaining HIPPA, 21 CFR Part 11 and GDPR compliance.

“We offer a full range of biometric services that cover the entire clinical trial lifecycle, resulting in robust data collection, analysis, and reporting,” said Jian Chen, CEO, EDETEK. “We help our partners ensure data quality and integrity through the orchestration of biostatistics, data management, advanced analytics, and integration of biometric data with all data collected.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”